SCHEMBL17217340

SCHEMBL17217340

Cc1ccc(CON=[C]c2cccc(C#N)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ GAA P10253 2/20 0.40
▸ DYRK1A Q13627 1/20 0.39
▸ CLK4 Q9HAZ1 1/20 0.39
▸ GRM5 P41594 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ CYP2A6 P11509 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAOB P27338 3/20 0.37
▸ POLB P06746 1/20 0.37
▸ KIF11 P52732 1/20 0.36
▸ BCHE P06276 1/20 0.36
▸ ACHE P22303 1/20 0.36
▸ HCRTR2 O43614 1/20 0.35
▸ FFAR1 O14842 2/20 0.35
▸ IDH1 O75874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17217339 1.00 NPC1 (0.41) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17218724 0.90 NPC1 (0.49) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17218720 0.90 NPC1 (0.49) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17219310 0.89 CYP2A6 (0.46) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17219308 0.89 CYP2A6 (0.46) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17217372 0.87 NPC1 (0.46) NPC1RAB9ASMN1; SMN2L3MBTL1GAA
SCHEMBL17215972 0.87 GRM5 (0.45) NPC1RAB9ASMN1; SMN2L3MBTL1GRM5
SCHEMBL17218824 0.87 IDO1 (0.44) SMN1; SMN2CLK4GRM5ALDH1A1MAPT
SCHEMBL17218823 0.87 IDO1 (0.44) SMN1; SMN2CLK4GRM5ALDH1A1MAPT
SCHEMBL17217656 0.87 VNN1 (0.43) NPC1RAB9ASMN1; SMN2L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 NPC1 1841/4885RAB9A 399/4885SMN1; SMN2 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback